PLAN for an Effective COVID-19 Response
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
Lilly’s Dave Ricks is passionate about diversity and inclusion at a crucial time.
Although women make up the majority of health care employees, men still dominate the corner office. Here are six ways to give women a fair shot at the top.
Teams often struggle to execute external licensing agreements and M&A transactions that can supplement internal innovation and revenue. Six factors can enhance performance.
A new global survey reveals patient priorities around engagement, innovation and impact, and how pharma companies can benefit by becoming more patient centric.
An advanced algorithm helps doctors identify patients at risk of developing a serious kidney complication, enabling hospitals to lower treatment costs and save lives.
Quantum computing has the potential to significantly accelerate, enhance the quality of, and reduce the costs of drug discovery.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
Launching an orphan treatment is more complicated than ever. Here’s how to successfully navigate the challenges.
The pandemic has transformed health care. Physicians expect long-term changes in how they interact with biopharma companies.
The medical aesthetics market will rebound, but it will be different than it was before. Players and investors must start envisioning—and planning for—their future now.
A big part of improving immunotherapy for patients may lie in digital technology and analytics.
As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
Pockets of opportunity await generic-drug companies that are prepared to adopt new strategies.
BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.
Indian Pharmaceutical Industry has been a global powerhouse for supply of affordable medicines. The publication explores Future of Work Thinking Around 5 Core Operating Pillars for Manufacturing.
The Indian pharmaceutical sector has faced significant disruptions across its value chain, including the quality function, due to Covid-19. For most pharmaceutical companies, the quality function has been plagued by several challenges such as unavailability of manpower, inadequate remote working infrastructure and significant volatility in supply and demand.
A 12- to 18-month timeline assumes that a vaccine progresses through all the various stages of testing without encountering significant issues.
New technologies are transforming the pharmaceutical industry’s approach to R&D. What’s happening now in the field—and what’s coming next?
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.
These curative treatments are often unique. They face a very different type of marketplace.
There are positive signs of potential benefits across multiple drug classes and candidates.
